المؤلفون: Jean-Pierre Zellweger, Antonio Spanevello, Miguel Villar, Rupak Singla, Lia D'Ambrosio, Zarir F Udwadia, Giesela F. Schecter, Alena Skrahina, Holly Anger, Jan-William C. Alffenaar, Saverio De Lorenzo, Alimuddin Zumla, Jose A. Caminero, Giovanni Battista Migliori, Tae Sun Shim, Giovanni Sotgiu, Rosella Centis, Won-Jung Koh, Paolo Castiglia, Elisabetta Zampogna, Giovanni Ferrara

المساهمون: Faculteit Medische Wetenschappen/UMCG, Microbes in Health and Disease (MHD)

المصدر: European Respiratory Journal
European Respiratory Journal; Vol 40
European Respiratory Journal, 40(6), 1430-1442. EUROPEAN RESPIRATORY SOC JOURNALS LTD

مصطلحات موضوعية: Male, Antitubercular Agents, TBNET, chemistry.chemical_compound, 0302 clinical medicine, Acetamides, Tuberculosis, Multidrug-Resistant, 030212 general & internal medicine, MYCOBACTERIUM-CHELONAE INFECTION, Middle Aged, multidrug-resistant tuberculosis, 3. Good health, Treatment Outcome, Tolerability, Meta-analysis, Female, Patient Safety, medicine.symptom, Delamanid, medicine.drug, Adult, safety, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, Adolescent, Efficacy, INTRACTABLE MULTIDRUG-RESISTANT, IN-VITRO ACTIVITY, MDR-TB, linezolid, 03 medical and health sciences, Internal medicine, MANAGEMENT, medicine, Humans, extensively drug-resistant tuberculosis, XDR-TB, tolerability, Adverse effect, Oxazolidinones, DOSAGE, COMPLEX, business.industry, DRUG-RESISTANT TUBERCULOSIS, Sputum, meta-analysis, efficacy, adverse events, Extensively drug-resistant tuberculosis, medicine.disease, Surgery, 030228 respiratory system, chemistry, Linezolid, UPDATE, TREATMENT OUTCOMES, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef39322d42ef6d49d5d4bd47f6b090e